Molecular Imaging and Contrast Agent Database (MICAD)
The Molecular Imaging and Contrast Agent Database (MICAD) is a collection of data comprising molecular imaging and contrast agents that have in vivo animal or human data published in peer-reviewed scientific journals 1, 2 . MICAD is part of the National Institute of Health (NIH) Common Fund and aims to promote research using molecular imaging probes and to facilitate the translation of preclinical findings to clinical practice [1] [2] [3] . As of March 2013 there were approximately 1 400 agents listed in MICAD. Of this, the majority were for positron emission tomography (PET) (41%), followed by single photon emission computed tomography (SPECT) (29%), optical imaging (14%), magnetic resonance imaging (MRI) (11%), ultrasound (2%), multimodal imaging (1%), X-ray/computer tomography (X-ray/CT) (1%) and photoacoustic imaging (1%).
Cancers are traditionally staged and monitored using invasive methods, for example biopsies or exploratory surgery, characterizing treatment response by a change in tumour volume 4 . These methods are limited however as biochemical changes happen much faster than morphological ones. Molecular imaging allows a repeated in vivo measurement of several critical molecular features such that molecular imaging has become indispensable in current medical practice 4 . Of the MICAD entries, ten agents target carbonic anhydrase IX (CA IX), Table 1 . CA IX is overexpressed in several solid cancer types in hypoxic conditions, while expression in normal tissues is minimal. CA IX is thus considered a marker for tumour hypoxia as it provides differentiation between normal and hypoxic tissue, allowing the opportunity for selective imaging of solid tumours. This paper presents the ten CA IX imaging agents in MICAD and outlines their effectiveness for imaging CA IX in vivo.
Insert Table 1 here 
Carbonic Anhydrase IX as a tumour marker
Carbonic anhydrase IX (CA IX) is a dimeric zinc metalloenzyme that catalyzes the reversible hydration of CO 2 to HCO 3 -and H + to play an important role in pH homeostasis 24 . Each CA IX monomer is comprised of an intracellular domain, a single transmembrane helix domain, an extracellular proteoglycan domain and an extracellular catalytic domain 25, 26 . CA IX is overexpressed in several solid cancer types, including cervical, clear cell renal cell, pancreatic, breast, bladder, head and neck, soft tissue and non-small cell lung carcinoma 8, 12 . In solid tumours hypoxia inducible factor 1 (HIF-1) regulates a signalling cascade involving ~100 genes, including CA IX 7 , to enable adaptive cellular functions to support tumour cell survival, proliferation and metastasis in hypoxia 27 . The extracellular pH (pH e ) of tumour cells is lower than in normal tissue owing to elevated metabolism leading to increased production and export of acidic metabolites such as lactic acid 22 . At a molecular level CA IX overexpression leads to dramatically increased production of HCO3 -and H + at the extracellular surface of hypoxic tumour cells.
The HCO3 -is actively transported into the cell to buffer pHi while the H + contributes to acidosis of the extracellular space 28 to support invasion and metastasis 27 . The proteoglycan domain makes CA IX unique among CAs, and is proposed to assist CA IX to function efficiently at a more acidic pH 25, 26 .
Solid tumour masses are heterogeneous and show significant variation in oxygen concentrations 18, 29 . These heterogeneously distributed areas of hypoxia are referred to as the "hypoxic fraction" and arise from the insufficient organization of blood vessels within the solid tumours 30 . Hypoxic tumours have a high metastatic potential associated with a more aggressive phenotype, this results in a resistance to radio-and chemotherapy and therefore a poor outcome for the patient 4, 13, 29, 31, 32 . Gray and co-workers 33 reported that tumour cells lacking oxygen were resistant to death via radiation by 2.5 to 3-fold compared to fully oxygenated cells 29, 33 . These results were obtained separately by other groups 34 . Hypoxia has been established as a key feature that can significantly influence tumour behaviour and predict a response to therapy 4, 29, 32 . There are several invasive and non-invasive methods available for the detection of tumour hypoxia, but these are not fully reliable 4, 32 . These techniques either yield a variable diagnosis or have functional limitations due to the incomplete penetration of the tumours or resistance to some tumour types 13, 18, 32 . For example, hypoxia can be determined post-mortem in animal models given pimonidazole by i.v. administration 30 minutes prior to sacrifice. Pimonidazole is a 2-nitroimidazole compound that is reduced in hypoxia, the reduced form can react with and stain intracellular macromolecules in hypoxic regions to provide generic, but selective hypoxia detection 18, 35 . Co-localization analysis between pimonidazole staining and ex vivo CA IX expression detected by monoclonal antibodies (mAbs) to CA IX has yielded conflicting results, this has been attributed to different levels of oxygen at which pimonidazole is reduced or CA IX overexpressed, respectively; local temporal fluctuations in hypoxia level; or non-hypoxia-related factors that affect CA IX expression 16 . For in vivo hypoxia measurements, an invasive oxygen electrode can be used but this is not practical for all cancer types and causes significant patient discomfort. CA IX offers several features that make it a promising clinically relevant candidate for diagnostic imaging 29, 31 . Firstly, the active site domain is extracellular and can be targeted by imaging agents that do not have to transverse the cell membrane 29 , and secondly it is expressed in few normal tissues but is overexpressed to high concentrations in hypoxic conditions with a long half-life 7, 31 . It has been postulated that while some cell lines may subvert known hypoxia mechanisms and that CA IX is not overexpressed in all cancer cell types, a vast array of human solid tumours typically overexpress CA IX 7, 31 .
Antibody and antibody fragment imaging agents that target CA IX

G250 and cG250 monoclonal antibodies and antibody fragments, A3 and CC7 monoclonal antibodies
Monoclonal antibodies (mAb) are a homogenous population of immunoglobulins (eg. IgG) directed against a single epitope 36 . G250 is a mAb that was isolated more than 20 years ago and the antigen identified much later as an epitope of CA IX 6, 37, 38 . cG250 is a chimeric form of G250 that was developed to be less immunogenic than G250 whilst retaining the CA IX antigen specificity (K a = 4 x 10 9 M -1 ) 6, 7, 10 . Antibody fragments have several advantages over parent antibodies in the IgG format for molecular imaging owing to altered physicochemical properties.
This includes more rapid clearance from the blood and normal tissues, reduced residence time, a reduction in the radiation absorbed by the bone marrow, improved tumour penetrationparticularly into hypoxic tumour regions, and potentially reduced immunogenicity 39 . The increased clearance of fragments has several caveats as the absolute tumour uptake may be lower while nonspecific uptake by other organs may be higher 12, 39 . In 2009, Neri and coworkers 18 reported the generation and characterization of two high-affinity human mAbs specific to extracellular CA IX, named A3 and CC7 18 . These are the first fully human mAbs with high affinity (nM) for CA IX, importantly they do not inhibit CA IX activity and specificity to CA IX over other forms of CA was also confirmed 18 . Due to limitations in antibody diffusion within solid tumour masses 40, 41, 42 , A3 and CC7 antibodies in the small immunoprotein (SIP) format were prepared with a lower molecular weight (~25 kDa) cf. A3 and CC7 with a molecular weight of 76 kDa when in the IgG format. Researchers have undertaken work using these mAbs and mAb fragments conjugated to a range of clinically used radionuclides for imaging CA IX using PET and SPECT, Table 2 .
Insert Table 2 here.
Directly radiolabelled CA IX antibodies
With direct radiolabelling the mAb structure remains virtually unchanged and retains high specificity for the target antigen. reacts to insert an iodine ortho to the hydroxyl groups of tyrosine residues of the antibody, Figure   1 49 . The iodogen reagent also limits oxidative damage to the protein during radiolabelling 8, 48 .
Insert Figure 1 here
131 I has a higher intensity gamma ray when compared to 124 I and 125 I, it is also widely available, relatively inexpensive and was the first to be established as a radiolabelling agent for cG250 45, 46, 50 . 131 I was however readily released from the tumour cells following internalization of 131 IcG250 and the abundant high energy gamma photons could affect normal tissues such as the bone marrow, limiting the dose of 131 I-cG250 that could be used therapeutically 50, 52 .
Additionally, the high energy single-photon emission compromises image quality 6 . With these drawbacks, research moved to the direct iodination of cG250 using 124 I ( blood was collected, the unbound 125 I-mAb removed and the activity quantified using a gamma counter. Radioactivity in the blood was high: the radioactivity was 5.5% that of the blood activity at 24 h p.i. which the authors attributed to a small amount of the tracer diffusing into blood cells.
For the biodistribution study, 1.295 MBq of 125 I-mAb was injected intravenously into mice and the radioactivity of both normal tissues and tumour measured using a gamma counter at a range of time points 8 . Uptake of 125 I-mAb by the tumour was significantly higher than for normal tissues, 4.9 ± 1.2%ID/g (% of the injected dose per gram of tissue) at 24 h p.i. 8 . For SPECT imaging, mice were injected with 5.55 MBq of 125 I-mAb and after 48 h planar static images (duration 30 s) were acquired using a gamma camera. In parallel a control study was also undertaken using a 100-fold molar excess of unlabelled mAb injected into the mouse 24 h prior to injection with 125 I-mAb. The SPECT results showed that the 125 I-mAb preferentially concentrated in the HT-29 tumour at 48 h p.i. however it also accumulated in the thyroid, while in the control study unlabelled mAb blocked accumulation of 125 I-mAb in both the tumour and the thyroid. Although the signal to noise ratio was promising, the high levels of radioactivity in the blood make 125 I-mAb currently unsuitable for as a diagnostic tool 8 .
Indirectly radiolabelled CA IX antibodies and antibody fragments
Direct radiolabelling of antibodies with most other radionuclides is not possible and instead an indirect approach with a host-linker moiety is needed. In this indirect labelling method the host coordinates to the radionuclide while the linker allows covalent attachment to the antibody or antibody fragment with minimal disruption to structure. A summary of host-linkers and their method of attachment to the CA IX antibody component are shown in Figure 2 . Brouwers et al 10 ( 89 Zr-Df-cG250 successfully labelled even small (~100 mg)
tumours. The 89 Zr-Df-cG250 PET images improved over time with optimal images taken at 72 h p.i..
The comparison of the RIS images acquired with 89 Zr-Df-cG250 to those acquired with 111 In-DTPA-cG250, allowed researchers to conclude that the tumour uptake of 89 Zr-Df-cG250 was identical to 111 In-DTPA-cG250 (5.0 ± 2.4 and 4.9 ± 2.9 %ID/g, respectively) as was the blood levels at the 72 h timepoint (1.4 ± 0.4 and 1.7 ± 0.7 %ID/g, respectively). The uptake of both antibodies was similar in other organs assessed, however the authors state that in some cases, the PET images produced using 89 Zr-Df-cG250 were highly superior to the 111 In-Df-cG250 images and therefore this agent may be of value in the planning an monitoring of RCC patients 10 . 111 In-DTPA-cG250 is not listed as a CA IX targeting agent in MICAD however the synthesis and imaging properties in patients with RCC metastases has been reported and showed improved visualization and a higher activity compared with 131 I-cG250 46 . Unlike 131 I, 111 In is a residualizing radionuclide, that is, one that is retained inside a cell as the radioactive catabolites are trapped in the lysosomes 46, 54 . Based on increasing evidence that cG250 can be internalized by CA IX expressing RCC the use of residualizing radionuclides was suggested as beneficial.
Previous studies had shown that labelling cG250 with the residualizing nuclides 88 Y and 177 Lu had approximately 3-4 times the activity of 125 I-cG250 at 7 days p.i. 46 . Due to the similarity between the RIS results for 111 In-DTPA-cG250 and 89 Zr-Df-cG250 in tumour uptake, blood level and also a similarity amongst other tissues, the authors suggest that 89 Zr could be re-classed as a residualizing radionuclide 54 .
Insert Figure 3 here 111 In-DOTA-cG250, 111 In-DOTA-cG250-Fab and 111 In-DOTA-cG250-F(ab) 2 (Table 1, entries 4, 5 and 6) [13] [14] [15] . To evaluate the potential of cG250 fragments as imaging agents Carlin and co-workers compared the binding affinity for the CA IX antigen of two low molecular weight fragments of cG250, cG250-Fab and cG250-F(ab) 2 , with the parent cG250 12 . The fragments were prepared via enzymatic degradation of the intact cG250 using the hydrolytic enzymes pepsin and papain to give cG250-F(ab) 2 and cG250-Fab, respectively 12, 39 . The F(ab) 2 fragment is bivalent (two antigen binding sites), whereas the Fab fragment is monovalent (one antigen binding site) 39 . cG250, cG250-Fab and cG250-F(ab) 2 were each conjugated to DOTA and then complexed to the residualizing radionuclide 111 In, Figure Table 3 .
Insert Figure 4 here
Insert Table 3 here
Athymic male mice with HT-29 tumours were injected with 1.6 MBq of each 111 In-DOTA-cG250 111 In-DOTA-cG250-Fab and 111 In-DOTA-cG250-F(ab) 2 for in vivo biodistribution studies. 111 In-DOTA-cG250 (tested at 2, 4 and 7 days p.i) showed a high uptake of radioactivity into the HT-29
tumour. At 2 days p.i. uptake (20.1 ± 4.8% ID/g) was similar to that obtained with two nonspecific 111 In labelled control antibodies, the specificity of the 111 In-DOTA-cG250 was however confirmed over the next 5 days as the tumour uptake increased, while uptake of the control antibodies decreased. Compared to 111 In-DOTA-cG250, the radiolabelled fragments were tested at 6 h and 24 h p.i due to faster clearance and showed a lower absolute tumour uptake. For F(ab) 2 uptake was 7.6 ± 1.4 and 9.3 ± 2.1% ID/g at 6 h and 24 h p.i., respectively, while for Fab uptake was lower again (3.6 ± 1.3 and 3.5 ± 1.7% ID/g at 6 h and 24 h p.i., respectively) due to a much faster clearance from circulation. Biodistribution was similar for all three 111 In-DOTAantibodies across other organs. The tumour/blood (T/B) and tumour/muscle (T/M) values were compared for all three agents, Table 4 . Both the F(ab) 2 and the Fab fragments showed an improvement in the T/B and T/M ratios between 6 h and 24 h p.i. with the T/B ratio for the Fab fragment increasing dramatically from 2.8 to 16.6, this ratio is higher than for the 111 In-DOTAcG250 at 7 days p.i., Table 4 .
Insert Table 4 here
To correlate 111 In-DOTA-cG250 to regions of perfusion, hypoxia and CA IX expression, PET images were compared to fluorescent images of the same tumour section stained with Hoechst 33342, pimonidazole and a CA IX fluorescent antibody at 2 days p.i. of 111 In-DOTA-cG250. The
Hoescht stain revealed high perfusion around the rim of the tumour and disorganised perfusion at the centre, the anti-correlation of the PET image. 2 and Fab fragments showed a diffuse uptake in the core of the tumour, where the CA IX production is high. The Fab fragment had the fastest blood clearance and from digital analysis of the images, the authors concluded that the Fab fragment was the most rapid and reliable indicator for CA IX expression in hypoxic tumour regions.
However, despite this conclusion, due to the lower absolute tumour uptake for both the fragments, and additional problems posed by the nonspecific tracer uptake and poor perfusion, the authors recommend using the intact 111 In-DOTA-G250 at 7 days p.i. as this gave the most sensitive and accurate detection of CA IX 12 . The late images of the 111 In-DOTA-cG250 were comparable to the early images of the fragments but the higher tumour/non-tumour contrast of 111 In-DOTA-cG250 would reduce imaging times.
89 Zr-Df-cG250-F(ab) 2 89 Zr-Df-cG250-F(ab) 2 is similar to that presented in Figure 3 
16
. A cohort of BALB nu/nu mice subcutaneously implanted with SCCNij3 cell xenograft tumours, a head and neck tumour model, were used to qualitatively determine the intratumoural distribution of radiolabeled cG250 via autoradiography and compared to 111 In-DTPA-cG250. The preparation of 111 In-DTPAcG250 is described by Troost et al 57 . It was found that the autoradiography uptake signal of 89 ZrDf-cG250-F(ab) 2 was very similar to that of 111 In-DTPA-cG250 with all correlations over two timepoints P<0.0001. The uptake of 111 In-DTPA-cG250 was much higher than 89 Zr-Df-cG250-F(ab) 2 (25.2 ± 6.2 %ID/g versus 2.68 ± 1.30 %ID/g) however this was expected due to the longer circulatory half-life of IgG 16 . That being said the 89 Zr-Df-cG250-F(ab) 2 showed a faster accumulation in CA IX rich regions at 4 h p.i.
Ten mice were injected with 6.85 ± 0.55 MBq of 89 Zr-Df-cG250-F(ab) 2 , eight mice (two groups of n = 4) were examined via a small animal PET imaging scanner at 4 and 24 h p.i. At 30 min prior to PET imaging, mice were injected with 80 mg/kg of pimonidazole (hypoxia marker). One minute before sacrifice, mice were injected with Hoechst 33342 (perfusion marker). The tumours were clearly visible in the PET images at both 4 and 24 h p.i.. The radioactive uptake of the 89 ZrDf-cG250-F(ab) 2 was compared to the positive area of the tumour stained for CA IX and pimonidazole in tumour sections. The standardized uptake value maximum (SUV max ) of 89 Zr-DfcG250-F(ab) 2 for tumour, muscle and tissue was determined, Table 5 . The kidneys and liver displayed high uptake of 89 Zr-Df-cG250-F(ab) 2 however this is a common side effect of using F(ab) 2 fragments: it is probable that the fragment can be reabsorbed, which may cause problems for imaging in the future.
A significant correlation (P<0.0001, r = 0.57-0.74) between the CA IX staining and radioactivity uptake was observed at both time points 16 . Similarly, there was a significant correlation (P<0.0001, r = 0.46-0.68) between pimonidazole (hypoxia) staining and tracer uptake. A strong positive correlation (P=0.0067, r = 0.93) was also observed between SUV max on the PET images and the measured tumour uptake found from the analysis of tissue (%ID/g), this correlation is similar to that found by Lawrentschuk et al for 124 I-cG250 in a SK-RC-52 model 7 . This study concluded that 89 Zr-Df-cG250-F(ab) 2 could be useful in determining CA IX-positive hypoxic areas for head and neck carcinomas via demonstrating a significant spatial correlation of 89 Zr-DfcG250-F(ab) 2 and CA IX expression however, the authors state that further research is required.
Insert Table 5 here 177 Lu-DTPA-A3-SIP, 177 Lu-DTPA-CC7-SIP (Table 1 , entry 8) 19 . Radiolabelled A3-SIP and CC7-SIP antibodies were prepared by covalent modification of a side chain lysine residue of the SIP by reaction with p-isothiocyanate benzyl DTPA (p-SCN-Bn-DTPA) to form a thiourea link, followed by coordination of 177 Lu radionuclide to the DTPA host, Figure 5 18, 58 Mass spectrometry analysis showed a stoichiometry of ~1.8 DTPA molecules per antibody molecule 18 .
The biodistribution of 177 Lu-DTPA-A3-SIP and 177 Lu-DTPA-CC7-SIP (0.259-0.407 MBq) was evaluated following injection into LS174T colorectal xenograft models (n = 4) and compared to 177 Lu-DTPA-SIP-L19 (a clinical stage antibody that targets neo-vasculature structures). The mice were sacrificed 24 h after SIP administration, the organs removed, weighed and the radioactivity counted. Very high kidney and high liver uptake values was observed for both 177 Lu-DTPA-A3-SIP and 177 Lu-DTPA-CC7-SIP. 177 Lu-DTPA-A3-SIP showed a ~4-fold lower tumour accumulation compared to 177 Lu-DTPA-SIP-L19 accumulation (2.4 %ID/g versus 9.3 %ID/g, respectively) however had an improved T/B ratio (16.7 versus 5.8, respectively). Biodistribution data for 177 Lu-DTPA-CC7-SIP was not presented. This study concluded that simultaneous use of vascular-targeting and hypoxia-targeting antibodies may be desirable to achieve a more homogenous distribution and detection of tumours.
Insert Figure 5 here
Small molecule imaging agents that target CA IX
Two of the ten agents in MICAD that target CA IX are small molecules. Tc-PS ( Tc-PS, with the aim of imaging CA IX expression to determine regional tumour hypoxia using SPECT. Tc is the most widely used radionuclide for diagnostic nuclear medicine (> 90%) 59 . It can be generated at low cost, it has a suitable half-life (6 h) and its gamma ray emission energy is not accompanied by beta emissions, allowing a more precise alignment of imaging detectors 59, 60 .
Additionally, its emission energy is 141 eV, enough to be detected by gamma cameras but low enough to not carry out significant damage to the body 20, 59 . 4-(2-Aminoethyl)benzenesulfonamide) (AEBS) was chosen as the core structure of After validation of the MRI method for pH determination, hyperpolarized H 13 CO -3 (200 μL, 40 mg/kg) was injected into three groups of mice with EL4 murine lymphoma tumours. Group 1 were untreated controls, group 2 were given sodium bicarbonate in the drinking water to increase the tissue pH and group 3 were given an ammonium chloride gavage to decrease the tissue pH 22 .
For comparison, several mice were injected with the pH sensitive molecule 3-aminopropylphosphonate (3-APP) so that 31 P spectra could be obtained for comparison. 3-APP is a nontoxic MRS-visible extracellular marker that is relatively unaffected by temperature or ionic strength, the chemical shift frequency of 3-APP is sensitive to pH allowing the determination of pH in vivo 61 . 13 which was highest in the aorta. Although minimal differences were shown in signal intensity between muscle/tumour tissue, a pH map was successfully calculated and a low pH value for the tumour mass was shown, demonstrating that it was possible to image tissue pH non-invasively in vivo. Comparing the untreated mice (tumour pH 6.71), NaHCO 3 treated mice (tumour pH 7.02) with NH 4 Cl (tumour pH 6.47) suggests that the H 13 CO -3 measurement reflects more of the extracellular pH. The authors suggest this could be due to the acquisition of spectra immediately after H 13 CO -3 is injected and that normally there is a higher concentration of bicarbonate in the extracellular environment. A limitation of the method was also highlighted, namely small differences in the rate at which H 13 CO -3 and 13 CO 2 lose polarization will lead to the calculated pH varying over time. Imaging therefore must be acquired with a few of the T 1 relaxation times. The T 1 s were found to be 10.1 ± 2.9s (n = 9) for H 13 CO -3 and 9.8 ± 2.5 s for 13 CO 2 (n = 7) with the presence of CA increasing this exchange.
Properties of antibodies and small molecules as imaging agents
Although antibodies provide excellent specificity towards their antigen, there are several factors that make tumour targeting with antibodies difficult. Solid tumours are heterogeneous masses and a common limitation of antibody-based imaging agents is slow or incomplete tissue distribution, especially to areas with poor vasculature 31 as the drugs cannot completely penetrate the tissue 62 .
The contributing factors to this include molecular size (IgG ~150 KDa), the antigen barrier and the high tumour interstitial pressure. Additionally, slow plasma clearance maintains high drug levels which complicate imaging and therapy 62 and present a high radiation dose risk to the bone marrow 13 . Rudnick and Adams have discussed in depth the interaction between the affinity, avidity and efficacy of antibodies in tumour targeting 63 . Although not the focus of this paper, the critical parameters they specify that affect a binding site are: antigen density, mAb internalization and metabolism and the mAb binding affinity 63 .
Antibody fragments may provide advantages over the intact antibodies. Their reduced molecular size (for example, cG250-F(ab´) 2 fragments ~100 kDa compared to intact cG250 ~ 150 kDa) may aid in tissue penetration and their reduced clearance time from the blood can result in higher tumour uptake compared to normal tissues. However, fragments may have increased renal uptake as they are reabsorbed by the renal tubular cells and may lead to radiation-induced nephrotoxicity 16, 39 . Similarly, scFv fragments of ~25 kDa may have excellent tumour penetration but their rapid clearance from the blood may be advantageous or disadvantageous. Other disadvantages include that they are monovalent and there is a possibility of aggregation 64, 65 . SIPs consist of two scFv fragments held via a hinge, making them bivalent, and their size of ~80 kDa means that they have a slower clearance time 64, 65 . They have an increased total affinity and have reduced immunogenicity 64, 65 . However, they have no effector functions and can be difficult to generate as the synthesis involves several steps 18, 64 .
Aromatic sulfonamides are the classical small molecule CA inhibitors that bind to the active site of CA 66 . The CA active sites are extremely tolerant to diverse and variable structures appended to the aromatic sulfonamide moiety 67 . It is possible to vary considerably the size, shape, charge, polarity, hydrophobicity etc. and still have nM CA inhibition. This tolerance allows finetuning of the biopharmaceutical and toxicological properties of the inhibitor via structural manipulations 67 .
Additionally, small molecules may be advantageous in their cost and ease of manufacture as well as their improved ADME and DMPK properties when compared to antibodies 67 . However, sensitivity, degradation, toxicity and clearance may all be considerably problematic with these compounds as well as specificity for CA IX over other CAs. To overcome these challenges the small molecule has to be designed very carefully to take the limitations in to account.
Imaging via PET is the most common imaging modality used with the agents described here.
PET is advantageous in that it allows the absolute quantitation of tracer uptake unlike determination of uptake via histological sections which is highly subjective 12 . As well as allowing the possibility of serial imaging, it is possible to image the whole tumour volume, instead of biopsy or tissue specimens 12 . PET displays a much higher sensitivity than SPECT (approximately 2-3 times the order of magnitude). Using SPECT however has the potential to increase the observational time window due to the longer half-life of the emitters used 68 . MRI has superior soft tissue contrast resolution, multiplanar image acquisition and functional imaging capabilities 69 . Of note is that only one of these agents has been designed for MRI. With the growth of MRI in hospitals and clinics, it is likely that more agents will be developed to use this modality which provides high resolution and superior soft tissue contrast. However, the ultimate deciding factor in the choice of imaging modality is the biological considerations of the system 68 .
Rahmim and Zaidi warn that in the biological context, generalized comparisons between modalities are not appropriate and instead they need to be performed on a case-by-case basis so that the correct imaging modality is selected 68 . 38.2 ± 18.3%ID/g, respectively, p = 0.029). This high uptake gave excellent PET image contrast, for example small intraperitoneal lesions (7 mm 3 ) were visualized with 89 Zr-Df-cG250 and were readily discriminated from the liver and spleen. The results from this study suggest that PET in RCC patients may be more sensitive using 89 Zr-Df-cG250 instead of 124 I-cG250 71 .
Conclusions
Of the MICAD entries, ten agents target CA IX, an antigen overexpressed in several solid cancer types in hypoxic conditions with expression in normal tissues is minimal. CA IX is a challenging diagnostic target for noninvasive molecular imaging, especially given the similarities in the active site for all 12 catalytically active human CAs. It is however an extremely important target as the detection and monitoring of hypoxic tumours can inform clinical decisions surrounding cancer therapy. Continued development of CA IX imaging agents will ideally balance patient safety, good tumour penetration and accurate localization of hypoxia. The ten MICAD agents described herein, highlight the scope and remaining opportunity for development of improved agents targeting CA IX imaging in oncology. 
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